Trial · NCT01991197
Results by group44
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 44
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| The Change in the Psoriasis Area and Severity Index (PASI) From Baseline to 16 Weeks in Psoriasis Patients With Type 2 Diabetes Treated With Sitagliptin Compared to Patients Treated With Gliclazide. | Sitagliptin | 9.5 | Inter-Quartile Range 7.8 to 9.6 | score on a scale | |
| The Change in the Psoriasis Area and Severity Index (PASI) From Baseline to 16 Weeks in Psoriasis Patients With Type 2 Diabetes Treated With Sitagliptin Compared to Patients Treated With Gliclazide. | Gliclazide | 9.4 | Inter-Quartile Range 7.6 to 12 | score on a scale | |
| The Number of Patricipants in the Sitagliptin and Gliclazide Arms With Adverse Events at 32 Weeks. | Sitagliptin | 6 | Participants | ||
| The Number of Patricipants in the Sitagliptin and Gliclazide Arms With Adverse Events at 32 Weeks. | Gliclazide | 10 | Participants | ||
| The Change in Quality of Life Scores From Baseline to 16 Weeks in the Sitagliptin and Gliclazide Arms. | Sitagliptin | DLQI | 0.0 | Inter-Quartile Range -1.0 to 1.0 | score on a scale |
| The Change in Quality of Life Scores From Baseline to 16 Weeks in the Sitagliptin and Gliclazide Arms. | Gliclazide | DLQI | -1.0 | Inter-Quartile Range -5.0 to 1 | score on a scale |
| The Change in Quality of Life Scores From Baseline to 16 Weeks in the Sitagliptin and Gliclazide Arms. | Sitagliptin | HAQ-8 | 0.0 | Inter-Quartile Range 0.0 to 0.0 | score on a scale |
| The Change in Quality of Life Scores From Baseline to 16 Weeks in the Sitagliptin and Gliclazide Arms. | Gliclazide | HAQ-8 | 0.0 | Inter-Quartile Range 0.0 to 0.0 | score on a scale |
| The Change in Quality of Life Scores From Baseline to 16 Weeks in the Sitagliptin and Gliclazide Arms. | Sitagliptin | HADS Anxiety | -1 | Inter-Quartile Range -3 to -1 | score on a scale |
| The Change in Quality of Life Scores From Baseline to 16 Weeks in the Sitagliptin and Gliclazide Arms. | Gliclazide | HADS Anxiety | 0 | Inter-Quartile Range -3 to 0 | score on a scale |
| The Change in Quality of Life Scores From Baseline to 16 Weeks in the Sitagliptin and Gliclazide Arms. | Sitagliptin | HADS Depression | 0 | Inter-Quartile Range -1 to 1 | score on a scale |
| The Change in Quality of Life Scores From Baseline to 16 Weeks in the Sitagliptin and Gliclazide Arms. | Gliclazide | HADS Depression | 0 | Inter-Quartile Range -3 to 1 | score on a scale |
| The Change in Quality of Life Scores From Baseline to 16 Weeks in the Sitagliptin and Gliclazide Arms. | Sitagliptin | EQ-5D | 0 | Inter-Quartile Range 0 to 0 | score on a scale |
| The Change in Quality of Life Scores From Baseline to 16 Weeks in the Sitagliptin and Gliclazide Arms. | Gliclazide | EQ-5D | -0.2 | Inter-Quartile Range -0.3 to 0 | score on a scale |
| The Effects of Treatment With Sitagliptin and Treatment With Gliclazide on Other Efficacy Endpoints. | Sitagliptin | PASI 50 | 1 | Participants | |
| The Effects of Treatment With Sitagliptin and Treatment With Gliclazide on Other Efficacy Endpoints. | Gliclazide | PASI 50 | 1 | Participants | |
| The Effects of Treatment With Sitagliptin and Treatment With Gliclazide on Other Efficacy Endpoints. | Sitagliptin | PASI 75 | 0 | Participants | |
| The Effects of Treatment With Sitagliptin and Treatment With Gliclazide on Other Efficacy Endpoints. | Gliclazide | PASI 75 | 0 | Participants | |
| The Effects of Treatment With Sitagliptin and Treatment With Gliclazide on Other Efficacy Endpoints. | Sitagliptin | PASI 90 | 0 | Participants | |
| The Effects of Treatment With Sitagliptin and Treatment With Gliclazide on Other Efficacy Endpoints. | Gliclazide | PASI 90 | 0 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01991197/results